Top Markets
Coin of the day
Metagenomi, Inc. Common Stock Metagenomi, Inc. Common Stock

Metagenomi, Inc. Common Stock

MGX
株式のランク #25869
Metagenomi, Inc. operates as a biotechnology company focused on gene editing,... Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
株価
$1.21
時価総額
$45.36M
変化(1日)
-2.82%
変化(1年)
-34.86%
US
取引 Metagenomi, Inc. Common Stock (MGX)

カテゴリー

Metagenomi, Inc. Common Stock(MGX)の配当利回りの履歴
Metagenomi, Inc. Common Stock(銘柄コード: MGX)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Metagenomi, Inc. Common Stock(MGX)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)